Savara shares are crushed as PhIII trial flunks primary, key secondaries — but they can’t stop believing
Investors are in no mood to hear biotechs tout the success of a “key” secondary endpoint when the pivotal Phase III flunks the primary goal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
